Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis | Zendy

Sofiati Dian | Zendy; Vycke Yunivita | Zendy; Ahmad Rizal Ganiem | Zendy; T. Pramaesya | Zendy; Lidya Chaidir | Zendy; Kurnia Wahyudi | Zendy; Tri Hanggono Achmad | Zendy; A. Colbers | Zendy; Lindsey te Brake | Zendy; Reinout van Crevel | Zendy; Rovina Ruslami | Zendy; Rob E. Aarnoutse | Zendy

Open Access

Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis

Author(s) -

Sofiati Dian,

Vycke Yunivita,

Ahmad Rizal Ganiem,

T. Pramaesya,

Lidya Chaidir,

Kurnia Wahyudi,

Tri Hanggono Achmad,

A. Colbers,

Lindsey te Brake,

Reinout van Crevel,

Rovina Ruslami,

Rob E. Aarnoutse

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01014-18

Subject(s) - placebo , meningitis , tuberculous meningitis , medicine , double blind , antibacterial agent , tuberculosis , randomized controlled trial , placebo controlled study , antibiotics , pharmacology , surgery , microbiology and biotechnology , biology , pathology , alternative medicine

High doses of rifampin may help patients with tuberculous meningitis (TBM) to survive. Pharmacokinetic pharmacodynamic evaluations suggested that rifampin doses higher than 13 mg/kg given intravenously or 20 mg/kg given orally (as previously studied) are warranted to maximize treatment response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research